Article
Oncology
Henry S. Friedman, Michael D. Prados, Patrick Y. Wen, Tom Mikkelsen, David Schiff, Lauren E. Abrey, W. K. Alfred Yung, Nina Paleologos, Martin K. Nicholas, Randy Jensen, James Vredenburgh, Jane Huang, Maoxia Zheng, Timothy Cloughesy
Summary: This study evaluated the efficacy of bevacizumab, alone or in combination with irinotecan, in recurrent glioblastoma patients. The results showed that bevacizumab, either alone or in combination, was well tolerated and active in treating recurrent glioblastoma.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Multidisciplinary Sciences
Andrew J. Brenner, John Floyd, Lisa Fichtel, Joel Michalek, Kunal P. Kanakia, Shiliang Huang, David Reardon, Patrick Y. Wen, Eudocia Quant Lee
Summary: The study investigated the safety and efficacy of Evo in combination with bevacizumab for treating bevacizumab refractory glioblastoma patients. Results showed a median overall survival of approximately 4.6 months with a median time to disease progression of 53 days from best response. The progression free survival at 4 months (PFS-4) on Evo-Bev treatment demonstrated a statistically significant improvement.
SCIENTIFIC REPORTS
(2021)
Review
Biochemistry & Molecular Biology
Jacob P. Fisher, David C. Adamson
Summary: The standard of care for high-grade gliomas includes surgical resection, radiation therapy, and temozolomide, which have improved patient survival rates. Besides temozolomide, there are several other FDA-approved treatments for HGG, with tumor treatment fields being the only one shown to significantly improve survival rates.
Article
Oncology
Jonathan P. S. Knisely, Howard A. Fine
Summary: The Oncology Grand Rounds series aims to provide clinical context to original reports published in the Journal. It includes case presentations, discussions on diagnostic and management challenges, literature reviews, and suggested management approaches by the authors. The goal is to help readers apply key study findings, including those from the Journal of Clinical Oncology, to their own clinical practice.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Medicine, Research & Experimental
Haibin Xia, Boyang Liu, Nanxiang Shen, Jinhua Xue, Siyu Chen, Hongbo Guo, Xiaozhong Zhou
Summary: The high expression of circRNA-0002109 in glioma promotes the malignant development of the tumor by regulating the miR-129-5P/EMP2 axis, affecting the proliferation, invasion, and migration of glioma cells.
MOLECULAR THERAPY-NUCLEIC ACIDS
(2022)
Article
Oncology
Gilbert Youssef, Rifaquat Rahman, Camden Bay, Wei Wang, Mary Jane Lim-Fat, Omar Arnaout, Wenya Linda Bi, Daniel N. Cagney, Yuh-Shin Chang, Timothy F. Cloughesy, Matthew DeSalvo, Benjamin M. Ellingson, Thomas F. Flood, Elizabeth R. Gerstner, L. Nicolas Gonzalez Castro, Jeffrey P. Guenette, Albert E. Kim, Eudocia Q. Lee, Jose R. McFaline-Figueroa, Christopher A. Potter, David A. Reardon, Raymond Y. Huang, Patrick Y. Wen
Summary: This study compared the performance of RANO criteria with modified RANO (mRANO) and immunotherapy RANO (iRANO) criteria in patients with newly diagnosed glioblastoma and recurrent GBM. The results showed similar correlations between PFS and OS for RANO and mRANO. Confirmation scans within 12 weeks after radiotherapy improved correlations in nGBM. Using postradiation MRI as the baseline scan had better correlation in nGBM compared to using pre-radiation MRI. Evaluation of FLAIR sequences did not improve the correlation. iRANO criteria did not provide significant benefit in patients receiving immune checkpoint inhibitors.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Multidisciplinary Sciences
Mohammad Hazaymeh, Ronja Loeber-Handwerker, Katja Doering, Tammam Abboud, Dorothee Mielke, Veit Rohde, Vesna Malinova
Summary: Approximately 25% of glioblastomas show corpus callosum infiltration at diagnosis, which is associated with poor prognosis. The extent of corpus callosum involvement ranges from partial unilateral to complete bilateral infiltration. The role of surgery in glioblastoma with corpus callosum involvement is controversial.
SCIENTIFIC REPORTS
(2022)
Article
Oncology
Motoo Nagane, Koichi Ichimura, Ritsuko Onuki, Daichi Narushima, Mai Honda-Kitahara, Kaishi Satomi, Arata Tomiyama, Yasuhito Arai, Tatsuhiro Shibata, Yoshitaka Narita, Takeo Uzuka, Hideo Nakamura, Mitsutoshi Nakada, Yoshiki Arakawa, Takanori Ohnishi, Akitake Mukasa, Shota Tanaka, Toshihiko Wakabayashi, Tomokazu Aoki, Shigeki Aoki, Soichiro Shibui, Masao Matsutani, Keisuke Ishizawa, Hideaki Yokoo, Hiroyoshi Suzuki, Satoshi Morita, Mamoru Kato, Ryo Nishikawa
Summary: This study evaluated the efficacy and safety of bevacizumab in Japanese patients with newly diagnosed glioblastoma and identified an expression classifier that may predict patient prognosis.
Article
Chemistry, Multidisciplinary
Yan Zou, Yibin Wang, Sen Xu, Yanjie Liu, Jinlong Yin, David B. Lovejoy, Meng Zheng, Xing-Jie Liang, Jong Bae Park, Yuri M. Efremov, Ilya Ulasovand, Bingyang Shi
Summary: A new type of GBM-cell membrane camouflaged and pH-sensitive biomimetic nanoparticles have been developed for combined TMZ and CDDP therapy for GBM. The results show that these nanoparticles can efficiently transport drugs across the blood-brain barrier and specifically target GBM, allowing for controlled release at GBM sites and demonstrating potent anti-GBM effects without obvious side effects.
ADVANCED MATERIALS
(2022)
Article
Oncology
Lei She, Lin Su, Chao Liu
Summary: The purpose of this study was to evaluate the safety, tolerability, and efficacy of a combination of BEV and re-RT for the treatment of rGBM. The results showed that this combination therapy was safe, tolerable, and effective in rGBM patients. Additionally, gross total resection prior to re-RT and selective concurrent temozolomide further improved patient PFS and OS.
FRONTIERS IN ONCOLOGY
(2022)
Article
Multidisciplinary Sciences
Weir-Chiang You, Hsu-Dung Lee, Hung-Chuan Pan, Hung-Chieh Chen
Summary: This study aimed to evaluate the effectiveness of combining re-irradiation and bevacizumab in treating patients with recurrent glioblastoma multiforme (GBM) resistant to bevacizumab monotherapy. The results showed that the group receiving re-irradiation had higher survival rates and longer median survival time than the group receiving no re-irradiation. The target volume of re-irradiation was identified as a significant factor for overall survival time after re-irradiation.
SCIENTIFIC REPORTS
(2023)
Article
Biochemistry & Molecular Biology
Shuai Wang, Jingheng Wu, Wujun Zhao, Miaomiao Li, Shaoyi Li
Summary: CEBPB and P4HA2 are upregulated in IDH1 wt gliomas and associated with poor prognosis. CEBPE promotes proliferation and TMZ resistance by inducing P4HA2 expression in glioma cells.
Article
Oncology
Xu Yang, Yan Zhang, Zhiwei Xue, Yaotian Hu, Wenjing Zhou, Zhiyi Xue, Xuemeng Liu, Guowei Liu, Wenjie Li, Xiaofei Liu, Xingang Li, Mingzhi Han, Jian Wang
Summary: This study found an increased expression of TRIM56 in glioblastoma, which promoted glioma progression by stabilizing cIAP1 through deubiquitination. The interaction between TRIM56 and cIAP1 may play a key role in glioma development. Additionally, TRIM56 could serve as a potential therapeutic molecular target and prognostic indicator for glioblastoma patients.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2022)
Article
Chemistry, Multidisciplinary
Melgious Jin Yan Ang, Jeehyun Yoon, Mingzhu Zhou, Han-Lin Wei, Yi Yiing Goh, Zhenglin Li, Jia Feng, Haifang Wang, Qianqian Su, Derrick Sek Tong Ong, Xiaogang Liu
Summary: Nanoparticles modified with ligands can cross the blood-brain barrier, endocytose into the lysosomes of glioblastoma cells, and undergo endolysosomal escape under photochemical ionization. Metronomic chemotherapy using dual-drug-loaded nanocarriers can induce an enhanced antitumor effect 3.5 times greater than standard chemotherapy.
ADVANCED MATERIALS
(2022)
Review
Oncology
Maximilian J. Mair, Marjolein Geurts, Martin J. van den Bent, Anna S. Berghoff
Summary: WHO grade II-III gliomas are rare primary brain tumors with longer median survival compared to grade IV glioblastoma. Treatment involves maximal safe resection and adjuvant therapies, with challenges in conducting clinical trials due to rarity and long follow-up times. The 2016 WHO Classification introduced a molecular diagnostic framework for more homogenous subgroups. Available evidence for adjuvant treatment was generated pre-molecular era, emphasizing the need for further research in this field.
CANCER TREATMENT REVIEWS
(2021)
Article
Oncology
M. Back, D. Jayamanne, D. Brazier, A. Newey, D. Bailey, G. Schembri, E. Hsiao, M. Khasraw, M. Wong, M. Kastelan, C. Brown, H. Wheeler
STRAHLENTHERAPIE UND ONKOLOGIE
(2020)
Article
Emergency Medicine
Kara L. Holloway-Kew, Tim R. Baker, Muhammad A. Sajjad, Mark A. Kotowicz, Patricia M. Livingston, Mustafa Khasraw, Sharon Hakkennes, Trisha L. Dunning, Susan Brumby, Richard S. Page, Alasdair G. Sutherland, Sharon L. Brennan-Olsen, Lana J. Williams, Julie A. Pasco
AUSTRALASIAN EMERGENCY CARE
(2020)
Review
Biochemistry & Molecular Biology
Aaron C. Tan, Malinda Itchins, Mustafa Khasraw
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2020)
Article
Oncology
Aaron C. Tan, David M. Ashley, Mustafa Khasraw
CLINICAL CANCER RESEARCH
(2020)
Review
Oncology
Aaron C. Tan, David M. Ashley, Giselle Y. Lopez, Michael Malinzak, Henry S. Friedman, Mustafa Khasraw
CA-A CANCER JOURNAL FOR CLINICIANS
(2020)
Review
Oncology
Mustafa Khasraw, David A. Reardon, Michael Weller, John H. Sampson
CLINICAL CANCER RESEARCH
(2020)
Review
Cell Biology
Hinda Najem, Mustafa Khasraw, Amy B. Heimberger
Summary: This article highlights the general resistance of brain tumors to immunotherapeutic agents and the important role of diverse immune cells in the immune microenvironment in the tumorigenesis process. Immune therapeutic combinations are identified as a crucial objective for future clinical studies.
Review
Oncology
Hao-Wen Sim, Evanthia Galanis, Mustafa Khasraw
Summary: New effective treatments for glioma are urgently needed, and PARP inhibitors are a promising option. They block the repair of DNA damage and may work synergistically with radiotherapy, chemotherapy, and immunotherapy. While low-grade gliomas have a better prognosis, recurrence and progression are still common.
Article
Biochemistry & Molecular Biology
Abhirami Venugopal, Agnes Michalczyk, Mustafa Khasraw, M. Leigh Ackland
Summary: Neuroendocrine neoplasms (NENs) are relatively rare tumors that occur primarily in the gastrointestinal tract and pancreas. The heterogeneity of these tumors presents challenges for diagnosis and treatment. This study identified differential expression of epithelial-mesenchymal transition (EMT) molecules in different tumor grades, suggesting their potential use in tumor stratification, prognosis, and therapeutic targeting.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Oncology
Alexander Yuile, Joe Q. Wei, Aditya A. Mohan, Kelly M. Hotchkiss, Mustafa Khasraw
Summary: Gliomas are common and deadly brain tumors with limited treatment options. The complex interaction between glioma cells and non-cancerous cells in the brain tissue, as well as variations depending on specific mutations, play a crucial role in glioma development. Understanding these interactions and mutations is essential for identifying future treatments for gliomas.
Meeting Abstract
Oncology
Eric Thompson, Daniel Landi, Eric Thompson, Eric Lipp, Bea Balajonda, James Herndon, Evan Buckley, Charlene Flahiff, Denise Jaggers, Kristin Schroeder, Dina Randazzo, Annick Desjardins, Maggie Johnson, Katherine Peters, Mustafa Khasraw, Michael Malinzak, Duane Mitchell, David Ashley, John Sampson
Meeting Abstract
Oncology
Kyle Walsh, Joanne Xiu, Giselle Lopez, Daniel Landi, Zachary Reitman, Sandeep Mittal, Andrew Brenner, Ekokobe Fonkem, Santosh Kesari, Surasak Phuphanich, Herbert Newton, Manjari Pandey, Emil Lou, Michael Glantz, Ashley Sumrall, Erin Dunbar, Macarena De La Fuente, W. Michael Korn, Mustafa Khasraw, David Ashley
Meeting Abstract
Oncology
Meredith Buxton, Brian Alexander, Donald Berry, Webster Cavenee, Howard Colman, John de Groot, Benjamin Ellingson, Gary Gordon, Mustafa Khasraw, Andrew Lassman, Wenbin Lee, Michael Lim, Ingo Mellinghoff, James Perry, Erik Sulman, Kirk Tanner, Michael Weller, Patrick Wen, W. K. Alfred Yung, Timothy Cloughesy
Meeting Abstract
Oncology
Nicole Cort, Alex Broom, Katherine Kenny, Alexander Page, Jennifer Durling, Casey Brown, Eric Lipp, David Ashley, Kyle Walsh, Margaret Johnson, Mustafa Khasraw
Meeting Abstract
Oncology
Annick Desjardins, Dina Randazzo, Vidya Chandramohan, Katherine Peters, Margaret Johnson, Daniel Landi, Mustafa Khasraw, Stevie Threatt, Chevelle Bullock, James Herndon, Eric Lipp, John Sampson, Allan Friedman, Henry Friedman, David Ashley, Darell Bigner